Sarepta Therapeutics's total assets for Q2 2025 were $3.68B, an increase of 6.19% from the previous quarter. SRPT total liabilities were $2.32B for the fiscal quarter, a -0.01% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.